Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study

Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Xuechan Li, Annie St Pierre, Anirudh Prahallad, Cristina Diaz-de-Heredia

Blood (2024) 144 (20): 2095–2106.

https://doi.org/10.1182/blood.2023022565

Published: 2024

Includes: Supplemental data

Journal Articles

Interest of Cytoreductive Therapy before Allogenic Hematopoietic Stem Cell Transplantation in Childhood Myelodysplastic Syndromes: A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Baptiste Le Calvez, Maxime Jullien, Jean-Hugues Dalle, Cécile Renard, Charlotte Jubert, Arthur Sterin, Catherine Paillard, Anne Huynh, Sarah Guenounou, Benedicte Bruno, Virginie Gandemer, Nimrod Buchbinder, Pauline Simon, Cecile Pochon, Anne Sirvent, Dominique Plantaz, Justyna Kanold, Fanny Rialland Battisti, Audrey Grain

Blood (2023) 142 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2023-181821

Published: 2023

Journal Articles

Ruxolitinib in Pediatric Patients with Treatment- Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study

Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Pantelia Roussou, Annie St. Pierre, Anirudh Prahallad, Cristina Díaz-de-Heredia

Blood (2022) 140 (Supplement 1): 1376–1378.

https://doi.org/10.1182/blood-2022-155708

Published: 2022

Journal Articles

Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study

Blood (2022) 140 (Supplement 1): 1882–1884.

https://doi.org/10.1182/blood-2022-162596

Published: 2022

Journal Articles

HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party

Blood (2022) 140 (Supplement 1): 5813–5815.

https://doi.org/10.1182/blood-2022-163219

Published: 2022

Journal Articles

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Blood (2022) 140 (Supplement 1): 8976–8978.

https://doi.org/10.1182/blood-2022-163056

Published: 2022

Journal Articles

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Blood (2022) 140 (Supplement 1): 8845–8847.

https://doi.org/10.1182/blood-2022-165954

Published: 2022

Journal Articles

Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study

Blood (2021) 138 (Supplement 1): 2862.

https://doi.org/10.1182/blood-2021-145858

Published: 2021

Journal Articles

Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia: Why Do Adolescents and Young Adults Outcomes Differ from Those of Children? a Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Blood (2021) 138 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2021-146769

Published: 2021

Journal Articles

Therapeutic Targets in Childhood B-Acute Lymphoblastic Leukemia : What about HER2/Neu?

Margaux Camuset, MD, Alice Huault, Audrey Grain, MD, Beatrice Clemenceau, PhD, Fanny Rialland, MD, Caroline Thomas, MD, Patrice Chevallier, MD PhD, Marie-Christine Béné, PharmSciD, PhD, Marion Eveillard

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-140273

Published: 2020

Journal Articles

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134774

Published: 2020

Journal Articles

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Erica Brivio, MD, Raoull Hoogendijk, MSc, Christophe Chantrain, MD PhD, Fanny Rialland, MD, Audrey Contet, Sarah Elitzur, MD, Luciano Dalla-Pozza, MBBS FRACP, Krisztian Kallay, MD, Chi Kong Li, MBBS,MD, Motohiro Kato, MD PhD, Inna V Markova, Dr., Kjeld Schmiegelow, Professor MD DMSc., Nicole Bodmer, Rob Pieters, MDPhDMSc, Christian Michel Zwaan, MD PhD

Blood (2019) 134 (Supplement_1): 3890.

https://doi.org/10.1182/blood-2019-126472

Published: 2019

Journal Articles

Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study

Blood (2018) 132 (7): 750–754.

https://doi.org/10.1182/blood-2018-01-829630

Published: 2018

Includes: Supplemental data

Journal Articles

Hematopoietic Stem Cell Transplantation May Lower the Risk of Leukemia in ELANE Neutropenia: Historical Trends from a French Severe Chronic Neutropenia Registry (FSCNR) Cohort

Jean Donadieu, MD, Blandine Beaupain, MsC, Fanny Rialland, MD, Catherine Paillard, MDPhD, Ouahiba Nachit, MsC, Claire Galambrun, MD, Virginie Gandemer, MDPhD, Yves Bertrand, MD, Benedicte Neven, MD, Despina Moshous, Flore Sicre De Fontbrune, MD, Regis peffault De La Tour, MDPhD, Marie Ouachee, MD, Christine bellanne Chantelot, MDPhD, Jean-Hugues Dalle, MD PhD

Blood (2017) 130 (Supplement 1): 546.

https://doi.org/10.1182/blood.V130.Suppl_1.546.546

Published: 2017

Journal Articles

Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

Blood (2016) 128 (22): 4018.

https://doi.org/10.1182/blood.V128.22.4018.4018

Published: 2016

Journal Articles

CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy

Marion Eveillard, PharmD, PhD, Victor Floc'h, Nelly Robillard, PhD, Camille Debord, Soraya Wuilleme, PharmD, PhD, Richard Garand, Fanny Rialland, MD, Caroline Thomas, Pierre Peterlin, MD, Thierry Guillaume, MD PhD, Philippe Moreau, Patrice Chevallier, MD PhD, Marie C Bene, PharmSciD, PhD

Blood (2016) 128 (22): 5268.

https://doi.org/10.1182/blood.V128.22.5268.5268

Published: 2016

Journal Articles

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

Anne-Flore Derache, MD, Fanny Rialland, MD, Gerard Michel, MD, Yves Perel, MD, Virginie Gandemer, MD PhD, Pascale Blouin, MD, Odile Minckes, MD, Arnaud Petit, MD PhD, Andre Baruchel, MD PhD, Benoit Brethon, MD

Blood (2016) 128 (22): 5190.

https://doi.org/10.1182/blood.V128.22.5190.5190

Published: 2016

Journal Articles

Efficacy and Safety of Unrelated Cord Blood Transplantation in Patients with Acquired Refractory Aplastic Anemia: A Phase II Study on Behalf of Eurocord and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Blood (2016) 128 (22): 2671.

https://doi.org/10.1182/blood.V128.22.2671.2671

Published: 2016

Journal Articles

Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome

Blood (2016) 127 (26): 3450–3457.

https://doi.org/10.1182/blood-2016-01-694349

Published: 2016

Includes: Supplemental data

Journal Articles

Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival

Florent Malard, Myriam Labopin, Patrice Chevallier, Thierry Guillaume, Alix Duquesne, Fanny Rialland, Sophie Derenne, Pierre Peterlin, Anne-Gaelle Leauté, Eolia Brissot, Marc Gregoire, Philippe Moreau, Philippe Saas, Béatrice Gaugler, Mohamad Mohty

Blood (2016) 127 (14): 1828–1835.

https://doi.org/10.1182/blood-2015-12-688739

Published: 2016

Includes: Supplemental data

NARROW

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study

Interest of Cytoreductive Therapy before Allogenic Hematopoietic Stem Cell Transplantation in Childhood Myelodysplastic Syndromes: A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Ruxolitinib in Pediatric Patients with Treatment- Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study

Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study

HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study

Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia: Why Do Adolescents and Young Adults Outcomes Differ from Those of Children? a Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Therapeutic Targets in Childhood B-Acute Lymphoblastic Leukemia : What about HER2/Neu?

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study

Hematopoietic Stem Cell Transplantation May Lower the Risk of Leukemia in ELANE Neutropenia: Historical Trends from a French Severe Chronic Neutropenia Registry (FSCNR) Cohort

Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

Efficacy and Safety of Unrelated Cord Blood Transplantation in Patients with Acquired Refractory Aplastic Anemia: A Phase II Study on Behalf of Eurocord and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome

Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only